Stefanie Hayoz

Head of Statistics

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stefanie Hayoz is the Head of Statistics at the Swiss Group for Clinical Cancer Research (SAKK) in Switzerland. Her research encompasses tumor immune dynamics, genomic profiling in cancer patients, and clinical outcomes associated with various treatment protocols, including neoadjuvant therapy and immunotherapy. Recent publications highlight her work on colorectal and breast cancer studies, as well as innovative approaches to prostate cancer treatment.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (7)

ANASTASIOS STATHIS

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

SWITZERLAND

View details

Jakob R Passweg

Head

University Hospital Basel

SWITZERLAND

View details

Ian S Dayes

McMaster University

CANADA

View details

ILARIA COLOMBO

SWITZERLAND

View details

Micaela Hernberg

Associate professor

University of Helsinki

FINLAND

View details

Eva Kimby

Karolinska University Hospital

SWEDEN

View details

Walter Paul Weber

Chief Physician

University Hospital Basel

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefanie Hayoz

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101)

Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment-A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report.

Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials.

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.

Six-month Rituximab-Lenalidomide regimen in advanced untreated Follicular Lymphoma: SAKK 35/10 Trial 10-year Update.

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue

Efficacy and tolerability of bacillus Calmette-Guérin strain Russia for the treatment of non-muscle-invasive bladder cancer: Analysis of a prospective registry

Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial

Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)

Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison

Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography-guided Salvage Radiotherapy Following Prostatectomy.

Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Collaborators (7)

ANASTASIOS STATHIS

Jakob R Passweg

Ian S Dayes

ILARIA COLOMBO

Micaela Hernberg

Eva Kimby

Walter Paul Weber

Make your next move.